OncoMatch/Clinical Trials/NCT06439914
First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy
Is NCT06439914 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies [89Zr]Zr-DFO-emapalumab for non small cell lung cancer.
Treatment: [89Zr]Zr-DFO-emapalumab — The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Prior therapy
Cannot have received: immunotherapy
Exception: Immunotherapy in neoadjuvant or adjuvant setting and have recurrence at least 12 months following completion of immunotherapy are eligible after discussion with the principle investigator.
No prior immunotherapy for current stage of NSCLC (Non Small Cell Lung Cancer). Immunotherapy in neoadjuvant or adjuvant setting and have recurrence at least 12 months following completion of immunotherapy are eligible after discussion with the principle investigator.
Lab requirements
Blood counts
cbc must be done within 28 days prior to pet imaging
Kidney function
bun, creatinine must be done within 28 days prior to pet imaging
Liver function
total bilirubin, ast, and alt must be done within 28 days prior to pet imaging
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Karmanos Cancer Institute · Detroit, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify